kashi-health-logo

Kashi Clinical Laboratories
10101 SW Barbur Blvd, Suite 200
Portland, OR 97219

1 877 879-1815
1000 characters left

Contact Information

Other Information

Practice Information

1-877-879-1815

Testing Menu

Pharmacogenetic Testing

Kashi Toxicology offers pharmacogenetic testing to help maximize effectiveness, minimize side effects, and help prevent interactions between medications. Knowing how a patient will metabolize certain medications based on their personal gene variants can help determine drug appropriateness and dosage. Practitioners can order by classification panels, specific genetic marker, or by selecting a custom profile.

Complete List of Pharmacogenetic Markers



ClassificationDrug ClassSelect Prescription DrugsGenetic Marker1-3**
Pain Management Antidepressants (SNRIs) Duloxetine, Venlafaxine CYP2D6
Antidepressants (TCAs) Amitriptyline, Clomipramine, Doxepin, Imipramine CYP2C19, CYP2D6
Muscle Relaxants Carisoprodol CYP2C19
NSAIDs* Celecoxib, Flurbiprofen CYP2C9
Opioids  Tramadol, Codeine, Oxycodone CYP2D6
Morphine COMT4
Psychotropic     Antidepressants (SNRIs*, SSRIs*) Atomoxetine, Duloxetine, Paroxetine, Venlafaxine CYP2D6
Escitalopram, Sertraline CYP2C19
Citalopram CYP2C19, CYP2D6
Antidepressants (TCAs*) Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Trimipramine CYP2C19, CYP2D6
Nortriptyline CYP2D6 only
Antipsychotics Clozapine, Haloperidol, Iloperidone, Risperidone, Zuclopenthixol CYP2D6
Aripiprazole CYP2D6, CYP3A4
Benzodiazepines Clobazam, Diazepam CYP2C19
Dietary supplement L-Methylfolate MTHFR5
Cardiac      Antiarrhythmics Flecainide, Propafenone CYP2D6
Anticoagulants Warfarin CYP2C9, VKORC1
Beta blockers Metoprolol CYP2D6
Dietary supplement L-Methylfolate MTHFR6
Platelet Inhibitors Clopidogrel CYP2C19 
Statins Simvastatin SLCO1B1
Epileptic Seizures/Chronic Pain Antiepileptic Carbamazepine HLA-A*31:01 & HLA-B*15:02
Phenytoin HLA-B*15:02, CYP2C9
HIV/AIDS NRTI* Abacavir HLA-B*15:02, CYP2C9
Hyperuricemia/Gout Xanthine Oxidase Inhibitor Allopurinol HLA-B*58:01
Gastrointestinal Proton Pump Inhibitors (PPIs) Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole CYP2C19
Rabeprazole CYP2C19, CYP3A4

*NRTI = nucleoside analogue reverse transcriptase inhibitor, NSAID = non-steroidal anti-inflammatory drug, SNRI = serotonin and norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant
** This list is not all inclusive. It is for your guidance only.

Urine Drug Testing

We are dedicated to providing healthcare professionals with accurate, timely, and cost-effective urine drug testing for improved patient health and safety.

Our laboratory delivers a constantly evolving test menu offering identification and quantitation for the latest and most commonly in prescribed medications and abused illicit drugs. Our highly-trained toxicology experts utilize state-of-the-art LC/MS technology to test for over 50 substances. Some of the most commonly tested substances are listed below.

Natural and Semi-Synthetic Opioids
Codeine
Morphine
Hydrocodone
Norhydrocodone
Hydromorphone
Oxycodone
Noroxycodone
Oxymorphone
Synthetic Opioids
Fentanyl
Norfentanyl
Methadone
EDDP (Methadone metabolite)
Tramadol
Tapentadol
Meperidine
Normeperidine
Benzodiazepines
Alpha-Hydroxyalprazolam
7-Amino-Clonazepam
Nordiazepam
Temazepam
Oxazepam
Diazepam
Stimulants
Amphetamine
Methylphenidate
Muscle Relaxants
Carisoprodol
Meprobamate
Illicit Drugs
Methamphetamine
Benzoylecgonine (Cocaine metabolite)
Phencyclidine (PCP)
6-MAM (Heroin metabolite)
MDMA (Ecstasy)
Mitragynine (Kratom)
Other Substances
Dextromethorphan
Dextrorphan
Ketamine
Norketamine
Naltrexone
Naltrexol
Zolpidem
References
  1. PharmGKB: The Pharmacogenetics Knowledgebase. https://www.pharmgkb.org/index.jsp
  2. PharmGKB: The Pharmacogentics Knowledgebase. Dosing Guidelines – CPIC. https://www.pharmgkb.org/view/dosing-guidelines.do?source=CPIC#
  3. US Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
  4. Sadhasivam S, and Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics. 2012; 13(15):1719-40.
  5. Gilbody S et al. Methylenetetrahydrofolate reductase (MTHF) genetic polmorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol. 2007; 165(1):1-13.
  6. Refsum H et al. The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with disease. J Nutr. 2006; 136:1731S-1740S.